Background: Non-alcoholic fatty liver disease (NAFLD) is the commonest cause of liver disease in the United Kingdom, and is predicted to become the leading indication for liver transplantation (LT) within the next 10 years. Key Messages: With rising demands on liver services, identifying those at risk of developing significant liver disease is important, so that risk factors for disease progression can be addressed. Emerging diagnostic techniques make it possible to diagnose significant fibrosis without the need for liver biopsy, and while there are currently no approved therapies for NAFLD, a specialist clinic can also provide access to clinical trials. For patients who develop cirrhosis, the presence of multiple comorbidities necessitates expertise in the selection and management of individuals requiring LT. Conclusions: A dedicated multidisciplinary NAFLD clinic facilitates rationalisation of services, improves patient outcomes, and provides access to emerging diagnostics and therapies.

1.
Armstrong MJ, Houlihan DD, Bentham L, et al: Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol 2012;56:234-240.
2.
Smits MM, Ioannou GN, Boyko EJ, et al: Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups. J Gastroenterol Hepatol 2013;28:664-670.
3.
Visscher TL, Heitmann BL, Rissanen A, et al: A break in the obesity epidemic? Explained by biases or misinterpretation of the data? Int J Obes (Lond) 2015;39:189-198.
4.
Wong RJ, Aguilar M, Cheung R, et al: Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015;148:547-555.
5.
Annual Report of the Chief Medical Officer (CMO), Volume 1, 2011.
6.
Than NN, Newsome PN: Non-alcoholic fatty liver disease: when to intervene and with what. Clin Med (Lond) 2015;15:186-90.
7.
Musso G, Gambino R, Cassader M, Pagano G: Prognosis and non-invasive methods to assess liver disease severity in non-alcoholic fatty liver disease (NAFLD): systematic review and meta-analysis. Ann Med 2011;43:617-649.
8.
Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al: Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-1292.
9.
Adams LA, Lymp JF, St Sauver J, et al: The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-121.
10.
Bhala N, Angulo P, van der Poorten D, et al: The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011;54:1208-1216.
11.
Angulo P, Kleiner DE, Dam-Larsen S, et al: Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015;149:389-397.e10.
12.
Brener S: Transient elastography for assessment of liver fibrosis and steatosis: an evidence-based analysis. Ont Health Technol Assess Ser 2015;15:1-45.
13.
Nobili V, Parkes J, Bottazzo G, et al: Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 2009;136:160-167.
14.
Musso G, Cassader M, Rosina F, et al: Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012;55:885-904.
15.
Newsome PN, Allison ME, Andrews PA: Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. Gut 2012;61:484-500.
16.
Wang X, Li J, Riaz DR, Shi G, Liu C, Dai Y: Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014;12:394-402.e1.
17.
Houlihan DD, Armstrong MJ, Davidov Y, et al: Renal function in patients undergoing transplantation for nonalcoholic steatohepatitis cirrhosis: time to reconsider immunosuppression regimens? Liver Transpl 2011;17:1292-1298.
18.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M: Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence and outcomes. Hepatology 2016;64:73-84.
19.
Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al: Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015;149:367-378.e5; quiz e14-e15.
20.
National Institute for Clinical Excellence (NICE): Type 2 Diabetes in Adults: Management, 2015.
21.
Astrup A, Carraro R, Finer N: Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36:843-854.
22.
Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, Sarigianni M, et al: Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013;159:262-274.
23.
Armstrong MJ, Hull D, Guo K, et al: Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol 2016;64:399-408.
24.
Armstrong MJ, Gaunt P, Aithal GP, et al: Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016;387:679-690.
25.
Mells G, Neuberger J: Long-term care of the liver allograft recipient. Semin Liver Dis 2009;29:102-120.
26.
Wong VW, Vergniol J, Wong GL, et al: Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010;51:454-462.
27.
Wong VW, Vergniol J, Wong GL, et al: Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012;107:1862-1871.
28.
National Institute for Clinical Excellence (NICE): Non-Alcoholic Fatty Liver Disease. Assessment and Management of Non-Alcoholic Fatty Liver Disease (NAFLD) in Children, Adults and Young People, 2016.
29.
Boettcher E, Csako G, Pucino F, Wesley R, Loomba R: Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2012;35:66-75.
30.
Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-1188.
31.
Sanyal AJ, Chalasani N, Kowdley KV, et al: Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-1685.
32.
Lago RM, Singh PP, Nesto RW: Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370:1129-1136.
33.
Piccinni C, Motola D, Marchesini G, Poluzzi E: Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011;34:1369-1371.
34.
Lecka-Czernik B: Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep 2010;8:178-184.
35.
Lavine JE, Schwimmer JB, Van Natta ML, et al: Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011;305:1659-1668.
36.
Chan JM, Darke AK, Penney KL, et al: Selenium- or vitamin E-related gene variants, interaction with supplementation, and risk of high-grade prostate cancer in SELECT. Cancer Epidemiol Biomarkers Prev 2016;25:1050-1058.
37.
Schürks M, Glynn RJ, Rist PM, Tzourio C, Kurth T: Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ 2010;341:c5702.
38.
Townsend SA, Newsome PN: Non-alcoholic fatty liver disease in 2016. Br Med Bull 2016;119:143-156.
39.
Cobbold JF, Raveendran S, Peake CM, et al: Piloting a multidisciplinary clinic for the management of non-alcoholic fatty liver disease: initial 5-year experience. Piloting a multidisciplinary clinic for the management of non-alcoholic fatty liver disease. Frontline Gastroenterol 2013;0:1-7.
40.
Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al: Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-873.
41.
Yalamanchili K, Saadeh S, Klintmalm GB, et al: Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl 2010;16:431-439.
42.
Demetris AJ, Adeyi O, Bellamy CO, et al: Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006;44:489-501.
43.
Hübscher SG: Transplantation pathology. Semin Liver Dis 2009;29:74-90.
44.
Johnston SD, Morris JK, Cramb R, et al: Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002;73:901-906.
45.
Laryea M, Watt KD, Molinari M, et al: Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007;13:1109-1114.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.